Lisata Therapeutics SG&A Expenses 2010-2025 | LSTA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Lisata Therapeutics sg&a expenses from 2010 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Lisata Therapeutics sg&a expenses from 2010 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$222.5B
Amgen (AMGN)	$159.7B
Gilead Sciences (GILD)	$139.4B
Vertex Pharmaceuticals (VRTX)	$121.3B
Bristol Myers Squibb (BMY)	$96.3B
GSK (GSK)	$78.4B
CSL (CSLLY)	$77.4B
Regeneron Pharmaceuticals (REGN)	$61.6B
Alnylam Pharmaceuticals (ALNY)	$41.2B
Argenex SE (ARGX)	$34.4B
BioNTech SE (BNTX)	$26.7B
Royalty Pharma (RPRX)	$20.4B
Biogen (BIIB)	$19.5B
Insmed (INSM)	$19.3B
Illumina (ILMN)	$15.6B
Genmab (GNMSF)	$14.2B
Genmab (GMAB)	$13.8B
Incyte (INCY)	$13.5B
Moderna (MRNA)	$12.7B
Exelixis (EXEL)	$12.4B
BioMarin Pharmaceutical (BMRN)	$11.2B
QIAGEN (QGEN)	$10.7B
Ascendis Pharma (ASND)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.4B
Exact Sciences (EXAS)	$10.2B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.4B
Bio-Techne Corp (TECH)	$8.2B
Roivant Sciences (ROIV)	$7.9B
Regencell Bioscience Holdings (RGC)	$7.3B